⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10613332 | 0.37 | — | — | |
| SCHEMBL31203085 | 0.35 | — | — | |
| SCHEMBL29889134 | 0.30 | — | — | |
| SCHEMBL29612863 | 0.30 | — | — | |
| SCHEMBL29908294 | 0.30 | — | — | |
| SCHEMBL30149517 | 0.30 | — | — | |
| Methane SCHEMBL23044967 | 0.30 | — | — | |
| SCHEMBL6559802 | 0.30 | — | — | |
| SCHEMBL156040 | 0.30 | — | — | |
| SCHEMBL7913046 | 0.30 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735958-A1 | PHOTORESIST PATTERNING IN MULTI-DEPTH NANOWELLS | Illumina, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| WO-2026044039-A2 | ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-02-26 | — | — | WO | claimed |
| US-20260038886-A1 | SULFONE-BASED ELECTROLYTE AND SECONDARY BATTERY COMPRISING SAME | DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-02-05 | — | — | US | claimed |
| US-20250010291-A1 | PHOTORESIST PATTERNING IN MULTI-DEPTH NANOWELLS | ILLUMINA, INC. | 2025-01-09 | — | — | US | claimed |
| WO-2025006431-A1 | PHOTORESIST PATTERNING IN MULTI-DEPTH NANOWELLS | ILLUMINA, INC. (US) | 2025-01-02 | — | — | WO | claimed |
| CN-118256468-A | Modified ToPif1 helicase and application thereof | 北京普译生物科技有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-118126984-A | Modified PAE CASDING helicase and application thereof | 北京普译生物科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-118126983-A | Modified MPK2 helicase and application thereof | 北京普译生物科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| WO-2024019272-A1 | SULFONE-BASED ELECTROLYTE AND SECONDARY BATTERY COMPRISING SAME | 재단법인대구경북과학기술원 | 2024-01-25 | — | — | WO | claimed |
| CN-115948112-A | Waterborne polyurethane coating and preparation process thereof | 成都鑫岩乔新材料科技有限公司 | 2023-04-11 | — | — | CN | claimed |
| CN-111378173-A | Force-responsive crosslinked polymer | 翁秋梅 | 2020-07-07 | — | — | CN | claimed |
| CN-111378180-A | Force-responsive crosslinked polymer | 翁秋梅 | 2020-07-07 | — | — | CN | claimed |
| CN-111378170-A | Force-responsive crosslinked polymer | 翁秋梅 | 2020-07-07 | — | — | CN | claimed |
| CN-100360554-C | peptide conjugates | UNIV KEIO (JP) | 2008-01-09 | — | — | CN | claimed |
| US-20070059376-A1 | Peptide conjugate | KEIO UNIVERSITY (JP) | 2007-03-15 | — | — | US | claimed |
| EP-1646625-A1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2006-04-19 | — | — | EP | claimed |
| CN-1747967-A | Peptide conjugate | UNIV KEIO (JP) | 2006-03-15 | — | — | CN | claimed |
| EP-1591451-A1 | PEPTIDE CONJUGATE | Keio University (JP) | 2005-11-02 | — | — | EP | claimed |
| WO-2005005416-A1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | WO | claimed |
| US-20260139068-A1 | ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2026-05-21 | — | — | US | disclosed |
| EP-4735958-A1 | PHOTORESIST PATTERNING IN MULTI-DEPTH NANOWELLS | Illumina, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026044039-A2 | ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-02-26 | — | — | WO | disclosed |
| US-20260038886-A1 | SULFONE-BASED ELECTROLYTE AND SECONDARY BATTERY COMPRISING SAME | DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-02-05 | — | — | US | disclosed |
| US-20260028420-A1 | ANTI-TUMOR ANTIBODIES | IMMUNOME INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260022193-A1 | METHODS OF TREATMENT USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 | ZYMEWORKS BC INC (CA) | 2026-01-22 | — | — | US | disclosed |
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC (CA) | 2025-11-06 | — | — | US | disclosed |
| US-12435157-B2 | Methods of using a bispecific antigen-binding construct targeting HER2 for the treatment of biliary tract cancers | ZYMEWORKS BC INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | ZYMEWORKS BC INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-09-25 | — | — | US | disclosed |
| US-20250276077-A1 | EPHA2 ANTIBODIES | IMMUNOME INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250277030-A1 | ANTI-NAPI2B ANTIBODIES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-09-04 | — | — | US | disclosed |
| EP-4605426-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2025-08-27 | — | — | EP | disclosed |
| EP-4605427-A1 | ANTI-NAPI2B ANTIBODIES AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2025-08-27 | — | — | EP | disclosed |
| EP-4594354-A1 | ANTIBODY DRUG CONJUGATES TARGETING C-MET AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2025-08-06 | — | — | EP | disclosed |
| US-20250235548-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-07-24 | — | — | US | disclosed |
| US-12357701-B2 | Anti-HER2 biparatopic antibody-drug conjugates and methods of use | ZYMEWORKS BC INC. (CA) | 2025-07-15 | — | — | US | disclosed |
| US-20250222128-A1 | ANTIBODY DRUG-CONJUGATES TARGETING C-MET AND METHODS OF USE THEREOF | ZYMEWORKS BC INC. (CA) | 2025-07-10 | — | — | US | disclosed |
| EP-4562011-A1 | IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF | Zymeworks BC Inc. (CA) | 2025-06-04 | — | — | EP | disclosed |
| US-20250170266-A1 | IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF | ZYMEWORKS BC INC. (CA) | 2025-05-29 | — | — | US | disclosed |
| CN-120051492-A | Anti-NAPI 2B antibodies and methods of use | 酵活英属哥伦比亚有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-120019075-A | Antibody drug conjugates targeting C-MET and methods of use | 酵活英属哥伦比亚有限公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2025093562-A1 | ANTIBODY-DRUG CONJUGATES HAVING A TAILOR-MADE DRUG-TO-ANTIBODY RATIO | BioNTech SE (DE) | 2025-05-08 | — | — | WO | disclosed |
| EP-4548936-A1 | ANTIBODY-DRUG CONJUGATES HAVING A TAILOR-MADE DRUG-TO-ANTIBODY RATIO | BioNTech SE (DE) | 2025-05-07 | — | — | EP | disclosed |
| CN-119948062-A | NAPI 2B-targeted antibody-drug conjugates and methods of use thereof | 酵活英属哥伦比亚有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-114025795-B | Methods of treating biliary tract cancer using bispecific antigen binding constructs that target HER2 | 酵活英属哥伦比亚有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-12286488-B2 | Anti-dinitolmide monoclonal antibodies and hybridoma cell strain that secretes them | JIANGNAN UNIVERSITY (CN) | 2025-04-29 | — | — | US | disclosed |
| WO-2025081282-A1 | ANTI-NAPI2B ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-04-24 | — | — | WO | disclosed |
| EP-4504798-A1 | ANTI-TUMOR ANTIBODIES | Immunome, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4499698-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2025-02-05 | — | — | EP | disclosed |
| EP-4499697-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2025-02-05 | — | — | EP | disclosed |
| US-20250010291-A1 | PHOTORESIST PATTERNING IN MULTI-DEPTH NANOWELLS | ILLUMINA, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20250009788-A1 | METHODS OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 IN COMBINATION WITH CDK4/6 INHIBITORS FOR THE TREATMENT OF BREAST CANCER | ZYMEWORKS INC. (CA) | 2025-01-09 | — | — | US | disclosed |
| WO-2025006431-A1 | PHOTORESIST PATTERNING IN MULTI-DEPTH NANOWELLS | ILLUMINA, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240424125-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-12-26 | — | — | US | disclosed |
| US-20240376154-A1 | BIS-INTERCALATING PEPTIDES, CONJUGATES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-11-14 | — | — | US | disclosed |
| CN-118922447-A | Folate receptor alpha-targeting antibody-drug conjugates and methods of use | 酵活英属哥伦比亚有限公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2023178451-A9 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-11-07 | — | — | WO | disclosed |
| EP-4312851-B1 | MECHANOCHROMIC PRESSURE SENSOR FOR SAFE AND EFFECTIVE TISSUE HANDLING IN MINIMALLY INVASIVE SURGERY | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2024-10-09 | — | — | EP | disclosed |
| US-12076400-B2 | Methods of using a bispecific antigen-binding construct targeting HER2 in combination with CDK4/6 inhibitors for the treatment of breast cancer | ZYMEWORKS BC INC. (CA) | 2024-09-03 | — | — | US | disclosed |
| US-20240269309-A1 | CAMPTOTHECIN ANALOGUES, CONJUGATES AND METHODS OF USE | ZYMEWORKS INC. (CA) | 2024-08-15 | — | — | US | disclosed |
| US-12050403-B2 | Organic-inorganic hybrid photoresist processing liquid composition | YOUNG CHANG CHEMICAL CO., LTD (KR) | 2024-07-30 | — | — | US | disclosed |
| CN-118256468-A | Modified ToPif1 helicase and application thereof | 北京普译生物科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240180576-A1 | MECHANOCHROMIC PRESSURE SENSOR FOR SAFE AND EFFECTIVE TISSUE HANDLING IN MINIMALLY INVASIVE SURGERY | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-06-06 | — | — | US | disclosed |
| CN-118126984-A | Modified PAE CASDING helicase and application thereof | 北京普译生物科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118126983-A | Modified MPK2 helicase and application thereof | 北京普译生物科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2024082056-A1 | ANTI-NAPI2B ANTIBODIES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024082051-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024082055-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-04-25 | — | — | WO | disclosed |
| EP-4347601-A1 | CAMPTOTHECIN ANALOGUES, CONJUGATES AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024065056-A1 | ANTIBODY DRUG CONJUGATES TARGETING C-MET AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-04-04 | — | — | WO | disclosed |
| CN-117715914-A | Camptothecin analogs, conjugates, and methods of use | 酵活英属哥伦比亚有限公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4312851-A1 | MECHANOCHROMIC PRESSURE SENSOR FOR SAFE AND EFFECTIVE TISSUE HANDLING IN MINIMALLY INVASIVE SURGERY | Fondazione Istituto Italiano di Tecnologia (IT) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024020684-A1 | IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF | ZYMEWORKS BC INC. (CA) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024019272-A1 | SULFONE-BASED ELECTROLYTE AND SECONDARY BATTERY COMPRISING SAME | 재단법인대구경북과학기술원 | 2024-01-25 | — | — | WO | disclosed |
| WO-2024006973-A1 | ENGINEERED HUMAN SERINE DEHYDRATASE ENZYMES AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023196824-A1 | ANTI-TUMOR ANTIBODIES | ATRECA, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196869-A1 | EPHA2 ANTIBODIES | ATRECA, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-4253421-A2 | ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023178451-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023178452-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2023-09-28 | — | — | WO | disclosed |
| CN-116199728-B | Galactose diselenide fluorescent probe and preparation method and application thereof | 南京工业大学 | 2023-09-19 | — | — | CN | disclosed |
| CN-116603073-A | Platelet-loaded small molecule pharmaceutical preparation, and preparation method and application thereof | 上海臻上医药科技有限公司 | 2023-08-18 | — | — | CN | disclosed |
| WO-2023141714-A1 | METHODS OF USING ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES IN THE TREATMENT OF CANCER | ZYMEWORKS BC INC. (CA) | 2023-08-03 | — | — | WO | disclosed |
| EP-3765525-B1 | ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | ZYMEWORKS BC INC (CA) | 2023-07-19 | — | — | EP | disclosed |
| CN-116199728-A | Galactose diselenide fluorescent probe and preparation method and application thereof | 南京工业大学 | 2023-06-02 | — | — | CN | disclosed |
| CN-116173237-A | Pharmaceutical formulation, method for the production thereof, and use thereof | 上海臻上医药科技有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-115948112-A | Waterborne polyurethane coating and preparation process thereof | 成都鑫岩乔新材料科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115948112-A | Waterborne polyurethane coating and preparation process thereof | 成都鑫岩乔新材料科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-111378141-B | Force-induced response supramolecular polymer | 厦门天策材料科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-11591579-B2 | Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-02-28 | — | — | US | disclosed |
| CN-111040204-B | Force-induced response dynamic polymer and application thereof | 厦门天策材料科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| EP-4087922-A1 | IMPROVED HUMAN METHYLTHIOADENOSINE/ADENOSINE DEPLETING ENZYME VARIANTS FOR CANCER THERAPY | Board of Regents, The University of Texas System (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-115244175-A | Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer treatment | 得克萨斯大学体系董事会 | 2022-10-25 | — | — | CN | disclosed |
| WO-2022201024-A1 | MECHANOCHROMIC PRESSURE SENSOR FOR SAFE AND EFFECTIVE TISSUE HANDLING IN MINIMALLY INVASIVE SURGERY | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2022-09-29 | — | — | WO | disclosed |
| US-11430973-B2 | Adhesive for lithium-ion electrode, electrode for lithium-ion battery and method for manufacturing electrode for lithium-ion battery | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2022-08-30 | — | — | US | disclosed |
| US-20220257789-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | EXELIXIS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-11396647-B2 | Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-26 | — | — | US | disclosed |
| CN-109152845-B | Comprising at least two (-CH) s within a ring2-CH2Conjugates of linkers of-O-) units and conjugation reagents | 宝力泰锐克斯有限公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3994150-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | Iconic Therapeutics, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| US-20220133903-A1 | METHODS OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR THE TREATMENT OF BILIARY TRACT CANCERS | ZYMEWORKS BC INC. (CA) | 2022-05-05 | — | — | US | disclosed |
| CN-109790178-B | Novel cytotoxic agents and conjugates thereof | 宝力泰锐克斯有限公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-108465112-B | Self-stabilizing linker conjugates | 西雅图基因公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3976098-A1 | METHODS OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR THE TREATMENT OF BILIARY TRACT CANCERS | Zymeworks Inc. (CA) | 2022-04-06 | — | — | EP | disclosed |
| CN-114222752-A | Anti-tissue factor antibody-drug conjugates and related methods | 伊科尼克治疗公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-111040110-B | Force-induced response dynamic polymer and application thereof | 厦门天策材料科技有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20220047683-A1 | HUMAN METHYLTHIOADENOSINE/ADENOSINE DEPLETING ENZYME VARIANTS FOR CANCER THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-17 | — | — | US | disclosed |
| CN-114025795-A | Methods of treating biliary tract cancer using bispecific antigen-binding constructs targeting HER2 | 酵活有限公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-113997650-A | Multilayer structure assembly with force-induced responsiveness | 厦门天策材料科技有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114001114-A | Flexible energy absorption system with concave corner structure | 厦门天策材料科技有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113980335-A | 3D printing dilatancy energy-absorbing structure and preparation method thereof | 厦门天策材料科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20210346508-A1 | ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2021-11-11 | — | — | US | disclosed |
| US-11147886-B2 | Drug-conjugated bi-specific antigen-binding constructs | ZYMEWORKS INC. (CA) | 2021-10-19 | — | — | US | disclosed |
| CN-106794259-B | Method of conjugating peptides or proteins using an agent comprising a leaving group comprising a PEG moiety | 宝力泰锐克斯有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20210170023-A1 | METHODS OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 IN COMBINATION WITH CDK4/6 INHIBITORS FOR THE TREATMENT OF BREAST CANCER | ZYMEWORKS BC INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| US-11000598-B2 | Anti-HER2 biparatopic antibody-drug conjugates and methods of use | ZYMEWORKS INC. (CA) | 2021-05-11 | — | — | US | disclosed |
| US-10933142-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS LTD (GB) | 2021-03-02 | — | — | US | disclosed |
| EP-3765525-A1 | ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Zymeworks Inc. (CA) | 2021-01-20 | — | — | EP | disclosed |
| WO-2021003399-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | ICONIC THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20200392108-A1 | ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS | IGENICA BIOTHERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2020242503-A1 | METHODS OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR THE TREATMENT OF BILIARY TRACT CANCERS | ZYMEWORKS BIOPHARMACEUTICALS INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| CN-111378180-A | Force-responsive crosslinked polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378176-A | Energy absorption method based on force-induced responsive cross-linked polymer with multiple networks | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378143-A | Energy absorption method based on force-induced response supramolecular polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378173-A | Force-responsive crosslinked polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378141-A | Force-induced response supramolecular polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378171-A | Force-responsive crosslinked polymer with multiple networks | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378177-A | Energy absorption method based on force-induced responsive polymer with hetero-network structure | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378170-A | Force-responsive crosslinked polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378179-A | Force-induced response supramolecular polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378140-A | Force-induced response supramolecular polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378436-A | Energy-efficient energy transfer polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378182-A | Force-induced responsive polymer with single-hybrid network structure | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378178-A | Energy absorption method based on force-induced response polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378137-A | Force-induced responsive polymer with multi-network structure | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378145-A | Force-induced response multiphase supramolecular block polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378144-A | Force-induced response supramolecular polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378169-A | Force-induced response hybrid crosslinked dynamic polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378139-A | Force-induced response supramolecular polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378174-A | Force-induced responsive polymer with multi-network cross-linked structure | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378181-A | Force-induced responsive polymer with single-hybrid network structure | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378172-A | Force-induced responsive polymer with multi-hybrid network structure | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378142-A | Force-induced response supramolecular polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378175-A | Force-induced response polymer with cross-linked structure | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111253610-A | Dynamic polymer foam composite material | 翁秋梅 | 2020-06-09 | — | — | CN | disclosed |
| CN-111218021-A | Vitrified dilatant polymer foam hybrid material | 翁秋梅 | 2020-06-02 | — | — | CN | disclosed |
| CN-111171364-A | Force-responsive polymer foam particle and preparation method thereof | 翁秋梅 | 2020-05-19 | — | — | CN | disclosed |
| CN-111171365-A | Force-responsive polymer foam composite material | 翁秋梅 | 2020-05-19 | — | — | CN | disclosed |
| CN-111166031-A | Dilatancy nature electronic product protective sheath/shell | 翁秋梅 | 2020-05-19 | — | — | CN | disclosed |
| CN-111171330-A | Force-responsive dilatancy polymer and method for realizing dilatancy | 翁秋梅 | 2020-05-19 | — | — | CN | disclosed |
| CN-111150196-A | Electronic device package containing dilatant component | 翁秋梅 | 2020-05-15 | — | — | CN | disclosed |
| CN-111150173-A | Shock attenuation sole and shock attenuation shoes | 翁秋梅 | 2020-05-15 | — | — | CN | disclosed |
| CN-111134409-A | Self-adaptive clothes | 翁秋梅 | 2020-05-12 | — | — | CN | disclosed |
| CN-111040110-A | Force-induced response dynamic polymer and application thereof | 翁秋梅 | 2020-04-21 | — | — | CN | disclosed |
| CN-111040204-A | Force-induced response dynamic polymer and application thereof | 翁秋梅 | 2020-04-21 | — | — | CN | disclosed |
| US-20200108150-A1 | REVERSIBLE COVALENT LINKAGE OF FUNCTIONAL MOLECULES | UCL BUSINESS LTD (GB) | 2020-04-09 | — | — | US | disclosed |
| US-20200108152-A1 | ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2020-04-09 | — | — | US | disclosed |
| US-10548982-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS LTD (GB) | 2020-02-04 | — | — | US | disclosed |
| WO-2019173911-A1 | ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | ZYMEWORKS INC. (CA) | 2019-09-19 | — | — | WO | disclosed |
| US-10294205-B2 | Allenamide as an orthogonal handle for selective modification of cysteine in peptides and proteins | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2019-05-21 | — | — | US | disclosed |
| US-20190142950-A1 | Reversible Covalent Linkage of Functional Molecules | UCL BUSINESS LTD (GB) | 2019-05-16 | — | — | US | disclosed |
| US-10174094-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS PLC (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20180193477-A1 | DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS | ZYMEWORKS BC INC. (CA) | 2018-07-12 | — | — | US | disclosed |
| US-20180147294-A1 | ANTIBODY-DRUG CONJUGATES, COMPOSITIONS AND METHODS OF USE | IGENICA BIOTHERAPEUTICS, INC. | 2018-05-31 | — | — | US | disclosed |
| EP-3322735-A1 | DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS | Zymeworks Inc. (CA) | 2018-05-23 | — | — | EP | disclosed |
| WO-2017161206-A1 | CONJUGATES CONTAINING CONDITIONALLY ACTIVE ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THEREOF, AND METHODS OF USE | HALOZYME, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-9717790-B2 | Sphingoglycolipid analogues | VICTORIA LINK LIMITED (NZ) | 2017-08-01 | — | — | US | disclosed |
| EP-2365969-B1 | Novel anti-biofilm agents | YISSUM RES DEV CO (IL) | 2017-03-22 | — | — | EP | disclosed |
| EP-3131875-A1 | ALLENAMIDE AS AN ORTHOGONAL HANDLE FOR SELECTIVE MODIFICATION OF CYSTEINE IN PEPTIDES AND PROTEINS | Nanyang Technological University (SG) | 2017-02-22 | — | — | EP | disclosed |
| CN-106414397-A | Allenamide as an orthogonal handle for selective modification of cysteine in peptides and proteins | 南洋理工大学 | 2017-02-15 | — | — | CN | disclosed |
| US-20170029373-A1 | ALLENAMIDE AS AN ORTHOGONAL HANDLE FOR SELECTIVE MODIFICATION OF CYSTEINE IN PEPTIDES AND PROTEINS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2017-02-02 | — | — | US | disclosed |
| WO-2017008169-A1 | DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS | ZYMEWORKS INC. (CA) | 2017-01-19 | — | — | WO | disclosed |
| US-20160303247-A1 | Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods | IGENICA BIOTHERAPEUTICS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| EP-3044236-A2 | MODIFIED ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF | Halozyme, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160176942-A1 | Reversible Covalent Linkage of Functional Molecules | UCL BUSINESS PLC (GB) | 2016-06-23 | — | — | US | disclosed |
| US-20160136267-A1 | SPHINGOGLYCOLIPID ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2016-05-19 | — | — | US | disclosed |
| US-9295729-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS PLC (GB) | 2016-03-29 | — | — | US | disclosed |
| WO-2015160307-A1 | ALLENAMIDE AS AN ORTHOGONAL HANDLE FOR SELECTIVE MODIFICATION OF CYSTEINE IN PEPTIDES AND PROTEINS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2015-10-22 | — | — | WO | disclosed |
| CN-104822656-A | Self-stabilizing linker conjugates | SEATTLE GENETICS INC | 2015-08-05 | — | — | CN | disclosed |
| EP-2889624-A2 | Reversible covalent linkage of functional molecules | UCL Business PLC (GB) | 2015-07-01 | — | — | EP | disclosed |
| WO-2015038984-A2 | MODIFIED ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF | HALOZYME, INC. (US) | 2015-03-19 | — | — | WO | disclosed |
| US-20150071923-A1 | MODIFIED ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF | HALOZYME, INC. | 2015-03-12 | — | — | US | disclosed |
| EP-2549276-B1 | Reversible covalent linkage of functional molecules | UCL BUSINESS PLC (GB) | 2015-02-25 | — | — | EP | disclosed |
| WO-2014200363-A1 | SPHINGOGLYCOLIPID ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2014-12-18 | — | — | WO | disclosed |
| US-20140363454-A1 | Antibody-Drug Conjugates, Compositions and Methods of Use | IGENICA BIOTHERAPEUTICS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| WO-2014197871-A2 | ANTIBODY-DRUG CONJUGATES, COMPOSITIONS AND METHODS OF USE | IGENICA BIOTHERAPEUTICS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| EP-2793585-A1 | ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS | Igenica Biotherapeutics, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8865909-B2 | Anti-biofilm agents | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-21 | — | — | US | disclosed |
| EP-2464654-B1 | THIOL PROTECTING GROUP | UCL BUSINESS PLC (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-20130224228-A1 | Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods | IGENICA, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013085925-A1 | ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS | IGENICA, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-2549276-A2 | Reversible covalent linkage of functional molecules | UCL Business PLC (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-20120190814-A1 | Thiol Protecting Group | UCL BUSINESS PLC (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120190579-A1 | Functionalisation of Solid Substrates | UCL BUSINESS PLC (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120190124-A1 | Reversible Covalent Linkage of Functional Molecules | UCL BUSINESS LTD (GB) | 2012-07-26 | — | — | US | disclosed |
| EP-2464654-A2 | THIOL PROTECTING GROUP | UCL Business PLC (GB) | 2012-06-20 | — | — | EP | disclosed |
| EP-2464972-A1 | REVERSIBLE COVALENT LINKAGE OF FUNCTIONAL MOLECULES | UCL Business PLC (GB) | 2012-06-20 | — | — | EP | disclosed |
| EP-2464974-A1 | FUNCTIONALISATION OF SOLID SUBSTRATES | UCL Business PLC (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-20110281921-A1 | NOVEL ANTI-BIOFILM AGENTS | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2011-11-17 | — | — | US | disclosed |
| EP-2365969-A1 | Novel anti-biofilm agents | Yissum Research Development Company of The Hebrew University of Jerusalem (IL) | 2011-09-21 | — | — | EP | disclosed |
| US-8013603-B2 | NMR-detecting cell, NMR-measuring method, and NMR-measuring apparatus | JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (JP) | 2011-09-06 | — | — | US | disclosed |
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| WO-2011018611-A1 | REVERSIBLE COVALENT LINKAGE OF FUNCTIONAL MOLECULES | UCL BUSINESS PLC (GB) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011018613-A1 | FUNCTIONALISATION OF SOLID SUBSTRATES | UCL BUSINESS PLC (GB) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011018612-A2 | THIOL PROTECTING GROUP | UCL BUSINESS PLC (GB) | 2011-02-17 | — | — | WO | disclosed |
| US-7887837-B2 | conjugate of adenosine diphosphate encapsulated in lipid in vesicle, linker, and substance that recognizes activated platelet and/or an injury site of blood vessel; platelet aggregation inducers | Takeoka, Shinji (JP) | 2011-02-15 | — | — | US | disclosed |
| US-20100264919-A1 | NMR-Detecting Cell, NMR-Measuring Method, and NMR-Measuring Apparatus | JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| WO-2010058402-A1 | NOVEL ANTI-BIOFILM AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2010-05-27 | — | — | WO | disclosed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-20090220422-A1 | Drug Delivery Material | KEIO UNIVERSITY (JP) | 2009-09-03 | — | — | US | disclosed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| CN-100478340-C | Pyrrole-2, 5-dithione derivatives as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-04-15 | — | — | CN | disclosed |
| CN-100478340-C | Pyrrole-2, 5-dithione derivatives as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-04-15 | — | — | CN | disclosed |
| US-20090029945-A2 | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| US-20080319017-A2 | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1977766-A1 | DRUG DELIVERY MATERIAL | Keio University (JP) | 2008-10-08 | — | — | EP | disclosed |
| EP-1646625-B1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080139616-A1 | Atherosclerosis; inflammatory diseases, Alzheimer's disease, dyslipidemia, metabolic syndrome; 2-isopropyl-5-phenyl-4-[(4-phenylbutyl)amino]isothiazole-3(2H)-thione 1,1-dioxide for example | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
| US-20080125396-A1 | Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides as Liver X Receptor Modulators | ATRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
| CN-101137629-A | Non-anilinic derivatives of isothiazol-3(2h)-thione 1,1-dioxides as liver x receptor modulators | ASTRAZENECA AB (SE) | 2008-03-05 | — | — | CN | disclosed |
| CN-101137628-A | Non-anilinic derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators | ASTRAZENECA AB (SE) | 2008-03-05 | — | — | CN | disclosed |
| CN-101137630-A | Non-anilinic derivatives of isothiazol-3(2h)-thione 1,1-dioxides as liver x receptor modulators | ASTRAZENECA AB (SE) | 2008-03-05 | — | — | CN | disclosed |
| CN-100360554-C | peptide conjugates | UNIV KEIO (JP) | 2008-01-09 | — | — | CN | disclosed |
| CN-101098861-A | Aniline derivatives of isothiazol-3 (2H) -thione 1, 1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2008-01-02 | — | — | CN | disclosed |
| EP-1838687-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1838685-A1 | DERIVATIVES OF ISOTHIAZOL-3 (2H)-THIONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1838686-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1262490-B1 | GPib-LIPID BOND CONSTRUCT AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2007-10-03 | — | — | EP | disclosed |
| EP-1838684-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-THIONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| US-20070059376-A1 | Peptide conjugate | KEIO UNIVERSITY (JP) | 2007-03-15 | — | — | US | disclosed |
| US-20060189663-A1 | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| US-20060189663-A1 | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| CN-1820003-A | Pyrrole-2, 5-dithione derivatives as liver X receptor modulators | ASTRAZENECA AB (SE) | 2006-08-16 | — | — | CN | disclosed |
| CN-1820003-A | Pyrrole-2, 5-dithione derivatives as liver X receptor modulators | ASTRAZENECA AB (SE) | 2006-08-16 | — | — | CN | disclosed |
| WO-2006073364-A1 | DERIVATIVES OF ISOTHIAZOL-3 (2H)-THIONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006073365-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-THIONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006073366-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006073363-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| EP-1646625-A1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| CN-1747967-A | Peptide conjugate | UNIV KEIO (JP) | 2006-03-15 | — | — | CN | disclosed |
| EP-1591451-A1 | PEPTIDE CONJUGATE | Keio University (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-6926884-B2 | GPIb-lipid bond construct and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-09 | — | — | US | disclosed |
| WO-2005005416-A1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | WO | disclosed |
| US-20030113262-A1 | Gpib-lipid bond construct and use thereof | IKEDA, YASUO (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-1262490-A1 | GPib-LIPID BOND CONSTRUCT AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2002-12-04 | — | — | EP | disclosed |
| US-6177059-B1 | DRUGS AND COMPLEXES WITH LIPIDS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-01-23 | — | — | US | disclosed |
| EP-0894807-A1 | GPIb-LIPID COMPLEX AND USES THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-02-03 | — | — | EP | disclosed |
| EP-0894807-A1 | GPIb-LIPID COMPLEX AND USES THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-02-03 | — | — | EP | disclosed |